AstraZeneca × Helix
AstraZeneca signed a multi-year agreement with Helix to gain access to its growing GenoSphere™ cohorts. [77] These cohorts provide de-identified Exome+ sequencing data linked with longitudinal clinical records, including diagnoses and lab results, to support drug discovery and development. [62, 63] Financial terms of the agreement were not disclosed. [63]
The asset
A multi-year agreement for access to Helix's GenoSphere™ cohorts, which consist of de-identified, comprehensive Exome+ genomic data linked to rich, longitudinal clinical data.
- 500k linked clinico-genomic records
The record
- Seller status
- Going concern
- Sector
- Population genomics
- Modalities
- genomic data, electronic health records
- Jurisdiction
- US
- Personal data
- The datasets are de-identified and the cohorts are fully consented to support targeted follow-on studies. [77, 62] The data includes an average EHR history of 13 years. [63]
What it means if you hold data
This deal highlights the increasing value of integrated, large-scale clinico-genomic data as a foundational resource for pharmaceutical R&D. [77] Access to continuously refreshed, deeply phenotyped datasets allows for accelerated research, from target validation to informing clinical trial design. [63]